Table of Contents
PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the launch, in the U.S. market, of lenalidomide capsules, a therapeutic equivalent generic version of REVLIMID (lenalidomide) Capsules approved by U. S. Food and Drug Administration.
With this volume-limited launch, Dr. Reddy’s is eligible for first-to-market, 180 days of generic drug exclusivity for lenalidomide capsules in 2.5 mg and 20 mg strengths.